TSH

Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)

Retrieved on: 
Donnerstag, Mai 30, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Patient, Headache, Patient satisfaction, Urinary tract infection, Endocrine Society, Erythema, TSH, Prevalence, FDA, Doctor of Pharmacy, Safety, Edema, Medication, Absorption, Hypothyroidism, Injection, Șaeș, Journal, Fatigue, Pharmaceutical industry

XP-8121 employs the Company’s XeriSol™ formulation technology to enable a novel once-weekly SC injection of levothyroxine.

Key Points: 
  • XP-8121 employs the Company’s XeriSol™ formulation technology to enable a novel once-weekly SC injection of levothyroxine.
  • The Phase 2 study included the following periods: Screening, Titration Period (2 to 8 weeks), and Maintenance Period (4 weeks).
  • Participants entered the study on a stable oral dose (≥ 3 months) with normal TSH and free T4 laboratory values.
  • Participants were receiving a daily oral levothyroxine dose of 83.7 ± 31.14 mcg (mean ± SD) at study entry.

New TSH Anywhere Curriculum Program Launches Nationwide in Response to School Dissatisfaction and Rise in Homeschooling

Retrieved on: 
Dienstag, Mai 14, 2024
Learning, Parent, Education, TSH, Schoolhouse, School, Student, Curriculum, Child, Nursing

NORTHPORT, N.Y., May 14, 2024 /PRNewswire/ -- The School House, proud home of the American Emergent Curriculum 501(c)(3), has officially launched its TSH Anywhere Curriculum Program nationwide in response to the surge of dissatisfaction in classrooms and the rise of homeschools across America. TSH Anywhere has been modeled after the success of The School House, a brick-and-mortar pre-K-6th grade school located in Long Island, New York, which is based on pedagogical science providing the only interconnected curriculum and empowered educator culture. The school has averaged a 70+ child waitlist for three years.

Key Points: 
  • NORTHPORT, N.Y., May 14, 2024 /PRNewswire/ -- The School House , proud home of the American Emergent Curriculum 501(c)(3), has officially launched its TSH Anywhere Curriculum Program nationwide in response to the surge of dissatisfaction in classrooms and the rise of homeschools across America.
  • TSH Anywhere has been modeled after the success of The School House, a brick-and-mortar pre-K-6th grade school located in Long Island, New York, which is based on pedagogical science providing the only interconnected curriculum and empowered educator culture.
  • With the launch of TSH Anywhere, we are providing our society with a curriculum focused on innovation and creation… a new American school for their children."
  • To learn more about The School House or the new TSH Anywhere program, please visit https://www.theschoolhouse.org/ or https://www.tshanywhere.org/ .

iClick Interactive Asia Group Limited Announces Termination of Merger Agreement

Retrieved on: 
Freitag, April 26, 2024
Mergers and acquisitions, Nature, The Company, Parent, Closing, Sub, Marketing, Business, Committee, TSH

HONG KONG, April 26, 2024 /PRNewswire/ -- iClick Interactive Asia Group Limited ("iClick" or the "Company") (NASDAQ: ICLK), a leading enterprise and marketing cloud platform in China that empowers worldwide brands with full-stack consumer lifecycle solutions, today announced the termination of the previously announced agreement and plan of merger, dated as of November 24, 2023 (the "Merger Agreement"), by and among the Company, TSH Investment Holding Limited (the "Parent") and TSH Merger Sub Limited (the "Merger Sub").

Key Points: 
  • HONG KONG, April 26, 2024 /PRNewswire/ -- iClick Interactive Asia Group Limited ("iClick" or the "Company") (NASDAQ: ICLK), a leading enterprise and marketing cloud platform in China that empowers worldwide brands with full-stack consumer lifecycle solutions, today announced the termination of the previously announced agreement and plan of merger, dated as of November 24, 2023 (the "Merger Agreement"), by and among the Company, TSH Investment Holding Limited (the "Parent") and TSH Merger Sub Limited (the "Merger Sub").
  • Since the delivery of the Closing Notice, the Company has been communicating and cooperating with the Parent, Merger Sub and their representatives towards the Closing, but the Parent and Merger Sub have failed to complete the Closing within ten (10) Business Days following the delivery date of the Closing Notice pursuant to Section 8.03(b) of the Merger Agreement.
  • On April 26, 2024, the Company (acting upon the recommendation of the Special Committee) sent a notice of termination to the Parent and the Merger Sub pursuant to Section 8.03(b) of the Merger Agreement, notifying the Parent and the Merger Sub that the Company is exercising its right to terminate the Merger Agreement pursuant to Section 8.03(b) of the Merger Agreement and demanding the Parent to pay the US$1,800,000 termination fee pursuant to Section 8.06(b) of the Merger Agreement by May 9, 2024.
  • As a result of the termination of the Merger Agreement, the proposed merger will not be completed.

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Mittwoch, Februar 28, 2024
ENDO, SAN, Congenital adrenal hyperplasia, Holocene, Carcinoid syndrome, Research, Entrepreneurship, Investment, FDA, Food, Webcast, Growth, Graves' ophthalmopathy, Primary hyperparathyroidism, PTH1R, Somatostatin, Conference, Endocrinology, Safety, TSH, Patient, CAH, Trial of the century, NDA, PHPT, Pharmaceutical industry

SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • ET Today
    SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the fourth quarter and full year ended December 31, 2023.
  • We also expect full results from our Phase 2 study in carcinoid syndrome in the first half of this year.
  • In December 2023, Crinetics reported an initial analysis of data from a subset of 27 patients.
  • Earlier today, February 28, 2024, Crinetics announced a private placement equity financing for gross proceeds of approximately $350 million.

iClick Interactive Asia Group Limited Announces Shareholders' Approval of Merger Agreement

Retrieved on: 
Freitag, März 8, 2024
The Company, ADS, Cayman Islands, Plan, Registrar, Marketing, Proxy, Cayman, TSH, EGM, Sub

Each shareholder has one vote for each Class A Share or 20 votes for each Class B Share.

Key Points: 
  • Each shareholder has one vote for each Class A Share or 20 votes for each Class B Share.
  • The Merger Agreement, the Plan of Merger and the transactions contemplated thereby, including the Merger, were approved by approximately 99.77% of the total votes cast at the EGM.
  • The completion of the Merger is subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement.
  • The Company will work with the other parties to the Merger Agreement towards satisfying all other conditions precedent to the Merger set forth in the Merger Agreement and completing the Merger as quickly as possible.

What do your blood test results mean? A toxicologist explains the basics of how to interpret them

Retrieved on: 
Dienstag, Februar 6, 2024
Glycated hemoglobin, Thyroid, BMP, Physical examination, Disorder, Hypothyroidism, Cell, BUN, Immune system, History, RBC, Heart, Blood urea nitrogen, Diabetes, Biomarker, Blood, Patient, Kidney, Triiodothyronine, Temperature, HB, TSH, Anemia, Nutrient, A1C, Disease, Thyroid hormones, Brain, Hematocrit, Fatigue, Waste, Health, HCT, Hormone, Plasma, Woman, Medical imaging

As part of my work, I rely on various health-related biomarkers, many of which are measured using conventional blood tests.

Key Points: 
  • As part of my work, I rely on various health-related biomarkers, many of which are measured using conventional blood tests.
  • Understanding what common blood tests are intended to measure can help you better interpret the results.
  • If you have results from a recent blood test handy, please follow along.

Normal blood test ranges

  • This range is essentially the upper and lower limits within which most healthy people’s test results are expected to fall.
  • To determine how your test results compare with the normal range, you need to check the reference interval listed on your lab report.
  • If you have results for a given test from different labs, your clinician will likely focus on test trends relative to their reference intervals and not the numerical results themselves.

Interpreting your blood test results

  • There are numerous blood panels intended to test specific aspects of your health.
  • These include panels that look at the cellular components of your blood, biomarkers of kidney and liver function, and many more.
  • This results from either lower than normal levels of red blood cells or a decrease in the quantity or quality of hemoglobin, the protein that allows these cells to transport oxygen.
  • A complete blood count panel measures various components of the blood to provide a comprehensive overview of the cells that make it up.
  • Low values of red blood cell count, or RBC, hemoglobin, or Hb, and hematocrit, or HCT, would indicate that the patient is suffering from anemia.
  • Providing additional information is the basic metabolic panel, or BMP, which measures the amount various substances in your blood.


With results from each of these panels, the health professional would assess the patient’s values relative to their reference intervals and determine which condition they most likely have. Understanding the purpose of blood tests and how to interpret them can help patients partner with their health care providers and become more informed about their health.
Brad Reisfeld does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

iClick Interactive Asia Group Limited Reports 2023 Half-Year Unaudited Financial Results

Retrieved on: 
Mittwoch, Dezember 13, 2023
EBITDA, TSH, Entrepreneurship, Projection, Investment, Collection, Share repurchase, Net, Event Marketing Solutions, ADS, Accounting, Marketing, GAAP, Proxy, Improper integral, Table, Mergers and acquisitions, Bank, Insurance, Retail, Video game, Cryptocurrency, Holding company, Parent

Revenue from Enterprise Solutions was US$21.5 million for the first half of 2023, compared with US$29.5 million for the first half of 2022.

Key Points: 
  • Revenue from Enterprise Solutions was US$21.5 million for the first half of 2023, compared with US$29.5 million for the first half of 2022.
  • Gross profit margin decreased to 25.0% for the first half of 2023 from 29.5% for the first half of 2022.
  • Total operating expenses were US$40.7 million for the first half of 2023, compared with US$52.3 million for the first half of 2022.
  • Adjusted net loss for the first half of 2023 was US$21.7 million, compared with US$20.5 million in the first half of 2022.

iClick Interactive Asia Group Limited Enters into a Definitive Merger Agreement for Going-Private Transaction

Retrieved on: 
Freitag, November 24, 2023
New Age, ADS, Marketing, Tripura Merger Agreement, Companies Act, Filter (signal processing), Harney Westwood & Riegels, Letter, Schedule, Ropes & Gray, Consortium, Proxy, Form 6-K, TSH, Class A share, Committee, The Company, AND, Support, Holding company, Security (finance), Cayman Islands, Limited, Mergers and acquisitions, Parent, Share (finance)

The Board, acting upon the unanimous recommendation of a committee of independent and disinterested directors established by the Board (the "Special Committee"), unanimously approved the Merger Agreement and the Merger, and unanimously resolved to recommend that the Company's shareholders vote to authorize and approve the Merger Agreement and the Merger.

Key Points: 
  • The Board, acting upon the unanimous recommendation of a committee of independent and disinterested directors established by the Board (the "Special Committee"), unanimously approved the Merger Agreement and the Merger, and unanimously resolved to recommend that the Company's shareholders vote to authorize and approve the Merger Agreement and the Merger.
  • The Special Committee negotiated the terms of the Merger Agreement with the assistance of its independent financial and legal advisors.
  • The Rollover Shareholders have agreed to vote all of the Shares beneficially owned by them in favor of the authorization and approval of the Merger Agreement and the Merger pursuant to the Support Agreement.
  • In connection with the Merger, the Company will prepare and mail a Schedule 13E-3 Transaction Statement (the "Schedule 13E-3").

EQS-News: Aareal Bank arranges refinancing of European portfolio for The Social Hub

Retrieved on: 
Donnerstag, Dezember 14, 2023
The Social Hub, Security, Growth, White & Case, Plain Green Loans, Social, Arrangement, Henri de Pardieu, Student, Student's Hotel, CBRE, TSH, White, Pinsent Masons, Travel, Work, Aareal Bank, Rabobank, Tourism

Wiesbaden, 27 November 2023 – Aareal Bank announces the successful closing of a € 566 million refinancing facility with The Social Hub (TSH), together with two participating lenders, one of which being Rabobank.

Key Points: 
  • Wiesbaden, 27 November 2023 – Aareal Bank announces the successful closing of a € 566 million refinancing facility with The Social Hub (TSH), together with two participating lenders, one of which being Rabobank.
  • Operated under TSH’s hybrid hospitality concept offering co-working, events, hotel, extended-stay rooms and student accommodation, the cross-border portfolio comprises 13 properties across the Netherlands, Spain, France and the UK.
  • Aareal Bank acted as the Arranger, Agent, and Security Agent of the senior loan, which is classified by Aareal as a Green Loan under its own Green Finance Framework.
  • “We are delighted to establish this relationship with such a unique hospitality brand and operator as TSH,” comments Michelle Weiss, Head of Hotel Properties at Aareal Bank.

Autobahn Therapeutics Announces Positive Topline Results from Phase 1 Study of ABX-002, its Lead Oral Treatment for Major Depressive Disorder

Retrieved on: 
Dienstag, November 7, 2023
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Trial of the century, IND, PD, MDD, Food, DSM-IV codes, CNS, MAD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, SAD, Development, Pharmacokinetics, Autobahn, PK, Biology, Safety, Vital signs, Therapy, TSH, Central nervous system, Pharmaceutical industry, Vaccine

ABX-002, a potent and selective thyroid hormone beta receptor (TRβ) agonist, is an orally administered small molecule being evaluated as a potential adjunctive treatment for people with major depressive disorder (MDD).

Key Points: 
  • ABX-002, a potent and selective thyroid hormone beta receptor (TRβ) agonist, is an orally administered small molecule being evaluated as a potential adjunctive treatment for people with major depressive disorder (MDD).
  • Results from the Phase 1 study:
    Across the range of doses tested, ABX-002 was safe and well-tolerated.
  • There were no serious adverse events and no premature discontinuations related to safety, with all 48 subjects completing the study.
  • “The positive data from this Phase 1 study represent a major milestone for ABX-002 and support its advancement into Phase 2 development,” said Kevin Finney, President and Chief Executive Officer of Autobahn Therapeutics.